D. Gupta, Revathi Tatavarthi, P. Shilpashree, N. M. Madan Mohan
{"title":"Severe cicatricial ectropion and lagophthalmos secondary to herpes zoster ophthalmicus in an immunocompetent child","authors":"D. Gupta, Revathi Tatavarthi, P. Shilpashree, N. M. Madan Mohan","doi":"10.4103/ijpd.ijpd_42_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_42_22","url":null,"abstract":"","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70760181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pediatric Psoriasis: A Closer View on Clinical Presentations","authors":"Dooha K. Alhamdi, Khalil Alhamdi","doi":"10.4103/ijpd.ijpd_15_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_15_22","url":null,"abstract":"","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70759349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hereditary sensory autonomic neuropathy (HSAN) falls under heritable neuropathies and is often misdiagnosed as leprosy leading to physical, emotional and financial burden to patients and their families. It presents as sensory and autonomic dysfunction leading to recurrent skin ulcers, scars, deformities of anaesthetic areas, Charcot joints, and decreased sweating. We report similar findings in an 11-year-old boy and his 10-year-old brother, in the form of ulcer, multiple healed scars and amputation of toes with reduced perception of touch, pain, temperature and vibration. No peripheral nerves were thickened, motor examination was within normal limits along with negative slit skin smear. Nerve conduction study revealed sensory polyneuropathy. X-ray of ankle joint showed degenerative changes. A diagnosis of HSAN type II with Charcot joint was made highlighting the importance of clinical history taking and physical examination. Parents were counselled regarding the management.
{"title":"Hereditary sensory and autonomic neuropathy type II in two brothers, a close differential of leprosy","authors":"Parul Verma, Sonal Sachan, Nishant Verma, Swastika Suvirya, Prakriti Shukla","doi":"10.4103/ijpd.ijpd_34_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_34_22","url":null,"abstract":"Hereditary sensory autonomic neuropathy (HSAN) falls under heritable neuropathies and is often misdiagnosed as leprosy leading to physical, emotional and financial burden to patients and their families. It presents as sensory and autonomic dysfunction leading to recurrent skin ulcers, scars, deformities of anaesthetic areas, Charcot joints, and decreased sweating. We report similar findings in an 11-year-old boy and his 10-year-old brother, in the form of ulcer, multiple healed scars and amputation of toes with reduced perception of touch, pain, temperature and vibration. No peripheral nerves were thickened, motor examination was within normal limits along with negative slit skin smear. Nerve conduction study revealed sensory polyneuropathy. X-ray of ankle joint showed degenerative changes. A diagnosis of HSAN type II with Charcot joint was made highlighting the importance of clinical history taking and physical examination. Parents were counselled regarding the management.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135949511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah Hamdy Soliman, Amany El Agamy El-Samadony, Ghada F. Rezk Hassan, Rania Ahmed El-Tatawy, Nesrin Sabry Gomaa
Abstract Lupus vulgaris (LV) is a cutaneous mycobacterial tuberculosis infection that is transmitted through lymphatic routes, hematogenous routes, or exogenous inoculation. It is infrequently reported after the Bacillus Calmette–Guérin (BCG) vaccine. In this report, we present a young child with LV at her BCG vaccine injection site as well as distant lesions of the chin.
{"title":"Childhood Lupus Vulgaris after Bacillus Calmette–Guérin Vaccine","authors":"Sarah Hamdy Soliman, Amany El Agamy El-Samadony, Ghada F. Rezk Hassan, Rania Ahmed El-Tatawy, Nesrin Sabry Gomaa","doi":"10.4103/ijpd.ijpd_19_23","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_19_23","url":null,"abstract":"Abstract Lupus vulgaris (LV) is a cutaneous mycobacterial tuberculosis infection that is transmitted through lymphatic routes, hematogenous routes, or exogenous inoculation. It is infrequently reported after the Bacillus Calmette–Guérin (BCG) vaccine. In this report, we present a young child with LV at her BCG vaccine injection site as well as distant lesions of the chin.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"140 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136257699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siti Nuraihan, MN Azmi, Sabeera Begum, Kin Fon Leong
Abstract Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.
{"title":"Dupilumab as a Combination Therapy to Oral Systemic Immunomodulators for Moderate-to-Severe Atopic Dermatitis for Skin of Color Children in Resource-Limited Setting: A Case Series","authors":"Siti Nuraihan, MN Azmi, Sabeera Begum, Kin Fon Leong","doi":"10.4103/ijpd.ijpd_94_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_94_22","url":null,"abstract":"Abstract Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136258009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ijpd.ijpd_100_22
D. Sathishkumar, A. Somasundaram, M. Chiramel, S. Korula
{"title":"Skin as a window to diagnose inborn errors of metabolism","authors":"D. Sathishkumar, A. Somasundaram, M. Chiramel, S. Korula","doi":"10.4103/ijpd.ijpd_100_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_100_22","url":null,"abstract":"","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70758922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Munisamy, C. Indra, J. Mathews, Rajendra Devanda
{"title":"Eczema coxsackium: An unusual manifestation of hand, foot, and mouth disease","authors":"M. Munisamy, C. Indra, J. Mathews, Rajendra Devanda","doi":"10.4103/ijpd.ijpd_33_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_33_22","url":null,"abstract":"","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70760123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Introduction: Atopic dermatitis is an inflammatory skin condition that begins in infancy, characterized by extreme skin dryness, excoriations, and erythema. A completely natural product with plant extracts and vegetable oils was developed to manage eczema and associated conditions in a mixed population including infants. Materials and Methods: An open-label, single-arm, single-center study was conducted to evaluate the safety and efficacy of the test product on eczema severity. A total of 58 subjects, including infants, children, and adults aged 0 months to 60 years, diagnosed with mild-to-moderate eczema, were included. The subjects applied a small amount of product on the affected area twice daily for 14 days. Three-Item Severity (TIS) score, Eczema Area and Severity Index (EASI) change, and symptomatic relief were assessed at various time points. Results: The TIS score in children significantly reduced from baseline at 24 h (12.22%), day 7 (52.26%), and day 14 (79.74%), (all P <0.0001). Similarly, a statistically significant reduction in EASI was observed in adults at day 7 (13.68%) and day 14 (30.87%) (all P < 0.0001), which continued to offer relief throughout the study duration. Irritation significantly decreased from baseline throughout the study duration to day 14 (75.17%) ( P < 0.0001). A significant reduction in other symptoms including dryness, itching, rashes, and edema was also seen from day 7 to day 14 ( P < 0.0001). Conclusion: The test product was found to be safe and effective in reducing eczema severity and associated conditions in infants and adults. It promotes the development of healthy neonatal skin and hence can be considered as a skin-healing cream for infants.
{"title":"Efficacy and Safety of a Skin Healing Cream in Mild-to-Moderate Eczema in a Mixed Population Including Infants: An Open-label, Single-arm Study","authors":"Shilpa Dhar, Trupti Patel, Arohi Bapna, Govindarajan Raghavan","doi":"10.4103/ijpd.ijpd_5_23","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_5_23","url":null,"abstract":"Abstract Introduction: Atopic dermatitis is an inflammatory skin condition that begins in infancy, characterized by extreme skin dryness, excoriations, and erythema. A completely natural product with plant extracts and vegetable oils was developed to manage eczema and associated conditions in a mixed population including infants. Materials and Methods: An open-label, single-arm, single-center study was conducted to evaluate the safety and efficacy of the test product on eczema severity. A total of 58 subjects, including infants, children, and adults aged 0 months to 60 years, diagnosed with mild-to-moderate eczema, were included. The subjects applied a small amount of product on the affected area twice daily for 14 days. Three-Item Severity (TIS) score, Eczema Area and Severity Index (EASI) change, and symptomatic relief were assessed at various time points. Results: The TIS score in children significantly reduced from baseline at 24 h (12.22%), day 7 (52.26%), and day 14 (79.74%), (all P <0.0001). Similarly, a statistically significant reduction in EASI was observed in adults at day 7 (13.68%) and day 14 (30.87%) (all P < 0.0001), which continued to offer relief throughout the study duration. Irritation significantly decreased from baseline throughout the study duration to day 14 (75.17%) ( P < 0.0001). A significant reduction in other symptoms including dryness, itching, rashes, and edema was also seen from day 7 to day 14 ( P < 0.0001). Conclusion: The test product was found to be safe and effective in reducing eczema severity and associated conditions in infants and adults. It promotes the development of healthy neonatal skin and hence can be considered as a skin-healing cream for infants.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136257701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A clinical study of dermatoses in neonatal intensive care unit in a tertiary health-care center","authors":"KB Kavya, S. Reddy, G. Guruprasad","doi":"10.4103/ijpd.ijpd_7_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_7_22","url":null,"abstract":"","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70760739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyper-IgE syndrome (HIES) is a rare group of primary immunodeficiency diseases characterized by elevated IgE levels, eosinophilia, recurrent pyoderma, ear infection, eczematous dermatitis, and pulmonary infection. The treatment depends on the clinical presentation of the disease. The eczematous skin lesions usually respond to a topical steroid, calcineurin inhibitors, and sometimes, based on severity, systemic drugs are given. The secondary infections are usually treated with oral and topical antibiotics. We are describing a case of HIES who presented with severe recalcitrant itchy oozy eczematous skin lesions which did not respond to conventional systemic drugs and were later on controlled with injection omalizumab. In addition, we have discussed the HIES in detail in the current article.
{"title":"A challenging case of recalcitrant Hyper-IgE syndrome successfully treated with omalizumab","authors":"Rashid Shahid, S. Pradhan, Suvesh Singh","doi":"10.4103/ijpd.ijpd_36_22","DOIUrl":"https://doi.org/10.4103/ijpd.ijpd_36_22","url":null,"abstract":"Hyper-IgE syndrome (HIES) is a rare group of primary immunodeficiency diseases characterized by elevated IgE levels, eosinophilia, recurrent pyoderma, ear infection, eczematous dermatitis, and pulmonary infection. The treatment depends on the clinical presentation of the disease. The eczematous skin lesions usually respond to a topical steroid, calcineurin inhibitors, and sometimes, based on severity, systemic drugs are given. The secondary infections are usually treated with oral and topical antibiotics. We are describing a case of HIES who presented with severe recalcitrant itchy oozy eczematous skin lesions which did not respond to conventional systemic drugs and were later on controlled with injection omalizumab. In addition, we have discussed the HIES in detail in the current article.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"23 1","pages":"318 - 321"},"PeriodicalIF":0.2,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49471445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：